Development, optimization, and in vitro evaluation of atorvastatin calcium and vinpocetine codelivery by solid lipid nanoparticles for cancer therapy

Abstract Background The main objective of the present study was to formulate, optimize and characterize solid lipid nanoparticles (SLNs) loaded with Atorvastatin Calcium (ATS) Vinpocetine (VIN) as a potential drug delivery system improve its solubility assess anti-tumor activity on cell lines. SLNs were formulated by emulsification high speed homogenization followed probe sonication. Central composite design selected for optimization. Drug: ratio, surfactant: co-surfactant ratio considered critical process parameters (CPP) effects quality attributes (CQA) i.e. particle size, percent entrapment efficiency (% EE) loading DL). Results optimized (F3) formulations characterized transmission electron microscopy (TEM), X- ray diffraction (X-RD) , in vitro release dialysis bag method stability studies. In line studies performed HepG2, MCF 7 melanoma B16 F10 line. F3 formulation showed size 323 ± 6 nm, poly dispersity index (PDI) 0.333 0.02, Zeta (ZP) − 30.4 0.66 emv % EE 64.69 1.1; 65.98 0.91 ATS VIN respectively. PBS pH 7.4 found be 89.45% 91.86%, respectively, up 24 h. Conclusions demonstrated that enhanced anti-cancer ATS, all stated lines when compared free drugs. Combination (CI) HEPG2 0.8, which signified synergistic effect. results exhibited is effective, stable had against